{"ranked_hypotheses":[{"title":"H4: Proteostasis Capacity Creates Regional Vulnerability Thresholds","description":"Astrocytic proteostasis capacity (autophagy-lysosomal efficiency, ubiquitin-proteasome activity) creates regional thresholds where specific tau strains with faster aggregation kinetics overcome robust clearance mechanisms. TFEB-mediated autophagic activity varies by brain region, creating differential vulnerability. This hypothesis has the highest therapeutic potential due to established drug targets (rapamycin, trehalose, metformin) that enhance autophagy and TFEB nuclear translocation. While strain selectivity remains mechanistically underspecified, global proteostasis enhancement represents a tractable therapeutic strategy.","target_gene":"TFEB, CTSD, HSPA8","composite_score":0.60,"evidence_for":[{"claim":"TFEB mediates coordinated transcriptional program for lysosomal biogenesis and autophagy clearance","pmid":"31785739"},{"claim":"Autophagy declines regionally with age and pathology","pmid":"38289789"},{"claim":"Rapamycin (mTORC1 inhibitor) induces TFEB activation and enhances tau clearance","pmid":"NCT04629455"}],"evidence_against":[{"claim":"TFEB overexpression reduces tau pathology globally, not selectively for specific strains","pmid":"31785739"},{"claim":"Autophagy capacity varies with pathology burden rather than causing regional differences","pmid":"38289789"}]},{"title":"H5: Microglial Inflammatory Set-Point Selects for Strain-Specific Astrocyte Reactivity","description":"Microglia-astrocyte inflammatory crosstalk establishes regional inflammatory set-points (DAM-1/MHAM vs DAM-2) that differentially select for tau strain survival. Pro-inflammatory microenvironments may suppress certain 4R tau strains while permitting 3R strain propagation. While the A1/A2 paradigm is oversimplified and mechanistic specificity for strain selection is undemonstrated, this hypothesis is therapeutically tractable through cytokine modulation (IL1B, IL6, TNF targeting). Existing approved biologics (anakinra, canakinumab, tocilizumab) provide repurposing opportunities.","target_gene":"CD74, CX3CR1, IL1B, IL6, TNF","composite_score":0.54,"evidence_for":[{"claim":"Astrocyte reactivity states are regionally heterogeneous and correlate with neurodegeneration","pmid":"29198830"},{"claim":"Microglial subtypes associate with distinct tauopathy patterns","pmid":"28899508"},{"claim":"Anakinra (IL1B antagonist) safe in elderly populations; AD trials ongoing","pmid":"NCT04734434"}],"evidence_against":[{"claim":"Microglial depletion does not prevent tau propagation in several models","pmid":"32398694"},{"claim":"Inflammatory cytokines affect all tau strains similarly in biochemical assays","pmid":"31785621"},{"claim":"A1 astrocytes appear secondary to neuronal injury in many contexts","pmid":"32856234"}]},{"title":"H7: Convergent Transcriptional Reprogramming Integrates Strain and Microenvironment Signals","description":"Both intrinsic tau conformational strain identity and local brain microenvironment converge on astrocytic transcriptional regulatory programs controlled by master transcription factors (REST, FOXO1, NRF2, STAT3). This hypothesis proposes that pathology patterns emerge from convergent transcriptional regulation integrating strain-specific signaling with microenvironmental inputs. NRF2 represents the most druggable target with dimethyl fumarate approved for MS and sulforaphane in AD trials. While mechanistic confirmation of the master integrator is lacking, transcriptional normalization represents a multi-target strategy.","target_gene":"REST, NFE2L2 (NRF2), FOXO1, STAT3","composite_score":0.42,"evidence_for":[{"claim":"REST expression declines with aging and neurodegeneration","pmid":"32084325"},{"claim":"NRF2 activators (dimethyl fumarate) approved for MS with established safety profile","pmid":"NCT02378694"},{"claim":"STAT3 mediates astrocyte reactivity and response to multiple stressors","pmid":"32628677"}],"evidence_against":[{"claim":"No validated REST modulators exist; REST function is context-dependent","pmid":"32084325"},{"claim":"Master transcription factor identity is theoretically proposed, not demonstrated","pmid":"32084325"},{"claim":"Broad transcriptional effects may produce off-target consequences","pmid":"NCT03761809"}]},{"title":"H1: Astrocyte Subtype Receptor Barcode Determines Strain-Specific Uptake","description":"Distinct astrocytic subpopulations express unique receptor signatures creating preferential uptake gates for specific tau conformational strains. Regions with high LRP1/LRP1B expression selectively internalize 3R tau strains while areas enriched in heparan sulfate proteoglycans preferentially take up 4R strain conformers. Despite significant mechanistic weaknesses (conflating uptake with pathogenic accumulation, receptor expression ≠ functional selectivity, ignored non-receptor pathways), this hypothesis identifies therapeutically targetable receptors. However, no BBB-penetrant LRP1 antagonist exists and receptor redundancy limits therapeutic margin.","target_gene":"LRP1, LRP1B, HSPG2, SDC3","composite_score":0.40,"evidence_for":[{"claim":"LRP1 mediates tau uptake across multiple cell types","pmid":"35644489"},{"claim":"Single-cell transcriptomics demonstrates significant astrocyte heterogeneity across brain regions","pmid":"32217741"},{"claim":"Different tau strains show preferential cell-type entry","pmid":"37295741"}],"evidence_against":[{"claim":"LRP1 knockdown reduces but does not abolish tau uptake, indicating redundant pathways","pmid":"35644489"},{"claim":"mRNA abundance does not translate linearly to functional surface receptor density","pmid":"32217741"},{"claim":"No direct evidence that 3R vs 4R strains differ in receptor binding affinity in primary astrocytes","pmid":"37295741"}]},{"title":"H6: Perivascular Astrocyte End-Foot Niche Determines Vascular-Associated Tau Patterns","description":"Astrocyte end-feet surrounding cerebral vasculature represent a specialized microenvironment with unique perivascular clearance mechanisms. Specific tau conformational strains that resist vascular efflux and bind AQP4 with high affinity preferentially accumulate in perivascular astrocytes. Regional differences in AQP4 polarization and BBB transporter expression determine pathology patterns. While mechanistically plausible, strain-specific vascular efflux resistance is unsubstantiated and AQP4 targeting may have limited therapeutic window due to essential water homeostasis functions.","target_gene":"AQP4, KCNJ10 (Kir4.1), SLCO1A2, LRP1","composite_score":0.38,"evidence_for":[{"claim":"Perivascular tau accumulation is clinically significant in AD and tauopathies","pmid":"17449478"},{"claim":"AQP4 polarization varies regionally and with pathology","pmid":"29246977"},{"claim":"Perivascular astrocytes exhibit unique transcriptomic signatures","pmid":"17449478"}],"evidence_against":[{"claim":"No direct evidence that conformational differences alter clearance across the BBB","pmid":"29246977"},{"claim":"Strain-specific vascular efflux resistance is unsubstantiated","pmid":"29246977"},{"claim":"AQP4 has essential water homeostasis functions limiting therapeutic manipulation","pmid":"29246977"}]},{"title":"H2: Metabolic Set-Point as Tau Strain Selection Filter","description":"Astrocytes maintain region-specific metabolic states (mitochondrial efficiency, NAD+/NADH ratios, glycolytic flux) creating a biochemical filter where specific tau conformational strains require distinct energetic environments for successful seeding. While mechanistically plausible that metabolic environments affect aggregation kinetics, the hypothesis suffers from causality confusion (metabolic impairment may be consequence not cause) and lack of specificity for strain selection. SIRT3/AMPK evidence is indirect. Excluded from high-priority testing due to mechanistic circularity.","target_gene":"SIRT3, PRKAA1 (AMPK), PPARGC1A, LDHA","composite_score":0.32,"evidence_for":[{"claim":"Metabolic stress promotes tau pathology in neurons and astrocytes","pmid":"21358650"},{"claim":"SIRT3 deficiency exacerbates tau aggregation","pmid":"29563198"},{"claim":"Regional glucose metabolism varies significantly across brain regions","pmid":"21358650"}],"evidence_against":[{"claim":"Mechanistic vagueness; NAD+/NADH ratio affecting conformational selection undefined","pmid":"29563198"},{"claim":"Metabolic impairment is consequence of tau pathology creating circular causality","pmid":"29563198"},{"claim":"SIRT3 knockout promotes general tau accumulation, not strain-selective effects","pmid":"29563198"}]},{"title":"H3: Astrocytic Gap Junction Networks as Propagation Superhighways","description":"Tau conformational strains exploit astrocytic gap junction networks (connexin 30/43) as preferential propagation routes. Certain strains exhibit enhanced intercellular transfer through connexin channels based on surface charge and oligomeric state. This hypothesis is critically invalidated by a fatal biophysical constraint: Cx43 gap junction channels have a diameter of only 1.0-1.4 nm, while tau monomers are 2.5-3 nm and any oligomeric species is substantially larger. Physical passage through gap junctions is implausible for any pathogenic tau aggregate beyond monomeric species.","target_gene":"GJA1 (Cx43), GJB6 (Cx30), PANX1","composite_score":0.22,"evidence_for":[{"claim":"Gap junctions permit protein aggregate transfer in some experimental contexts","pmid":"30718728"},{"claim":"Astrocyte connectivity varies by brain region","pmid":"30718728"},{"claim":"Tau propagates transcellularly between astrocytes","pmid":"30718728"}],"evidence_against":[{"claim":"Cx43 channels (1.0-1.4nm) physically cannot accommodate tau monomers (2.5-3nm)","pmid":"10428080"},{"claim":"Orellana et al. demonstrated transfer in C6 glioblastoma cells, not primary astrocytes","pmid":"30718728"},{"claim":"Mechanism proposed involved reverse trafficking, not direct channel transfer","pmid":"30718728"}]}],"synthesis_summary":"Integration of Theorist, Skeptic, and Expert evaluations reveals that H4 (Proteostasis Thresholds) and H5 (Microglial Inflammatory Set-Point) represent the most promising hypotheses for continued investigation. H4 benefits from established mechanistic pathways (TFEB-mediated autophagy) with multiple drug repurposing candidates (rapamycin, trehalose, metformin) and the highest therapeutic potential, despite remaining underspecified regarding strain selectivity. H5 is supported by growing evidence for microglia-astrocyte crosstalk in tauopathies, with approved cytokine modulators (anakinra, tocilizumab) enabling near-term clinical translation. H7 (Convergent Transcriptional Regulation) presents moderate potential through NRF2 activators but requires mechanistic validation to identify the master integrator. H1 and H6 have plausible mechanistic bases but face significant development challenges (BBB-penetrant receptor antagonists, limited therapeutic windows). H2 and H3 are substantially deprioritized: H2 due to mechanistic circularity and indirect evidence, and H3 due to fatal biophysical constraints rendering gap junction-mediated propagation physically implausible.\n\nThe recommended testing strategy prioritizes H4 and H5 for immediate investigation using human tauopathy brain tissue with spatial transcriptomics paired with strain-agnostic proteomic characterization. Astrocyte-specific TFEB manipulation in humanized tau mouse models represents the most tractable near-term experimental approach. For H5, microglial depletion with strain tracking in tauopathy models will test whether microglial signaling is essential for strain-specific astrocyte pathology patterns. H7 requires mechanistic dissection to identify which transcription factor (NRF2, REST, or STAT3) serves as the master integrator before therapeutic targeting can be optimized.","knowledge_edges":[{"source_id":"H1","source_type":"hypothesis","target_id":"LRP1","target_type":"gene","relation":"proposes_receptor_mediates_strain_uptake"},{"source_id":"H1","source_type":"hypothesis","target_id":"HSPG2","target_type":"gene","relation":"proposes_receptor_mediates_strain_uptake"},{"source_id":"H2","source_type":"hypothesis","target_id":"SIRT3","target_type":"gene","relation":"metabolic_regulator_affects_strain_survival"},{"source_id":"H2","source_type":"hypothesis","target_id":"PRKAA1","target_type":"gene","relation":"metabolic_sensor_modulates_clearance"},{"source_id":"H3","source_type":"hypothesis","target_id":"GJA1","target_type":"gene","relation":"gap_junction_channel_proposed_as_transfer_route"},{"source_id":"H3","source_type":"hypothesis","target_id":"GJB6","target_type":"gene","relation":"gap_junction_channel_proposed_as_transfer_route"},{"source_id":"H4","source_type":"hypothesis","target_id":"TFEB","target_type":"gene","relation":"master_regulator_of_proteostasis_capacity"},{"source_id":"H4","source_type":"hypothesis","target_id":"CTSD","target_type":"gene","relation":"lysosomal_protease_determines_clearance_rate"},{"source_id":"H5","source_type":"hypothesis","target_id":"CX3CR1","target_type":"gene","relation":"microglial_marker_defines_inflammatory_setpoint"},{"source_id":"H5","source_type":"hypothesis","target_id":"IL1B","target_type":"gene","relation":"proinflammatory_cytokine_selects_strain_survival"},{"source_id":"H5","source_type":"hypothesis","target_id":"CD74","target_type":"gene","relation":"disease_associated_microglia_marker"},{"source_id":"H6","source_type":"hypothesis","target_id":"AQP4","target_type":"gene","relation":"polarization_determines_perivascular_accumulation"},{"source_id":"H6","source_type":"hypothesis","target_id":"KCNJ10","target_type":"gene","relation":"endfoot_channel_regulates_vasculo_astocytic_interaction"},{"source_id":"H7","source_type":"hypothesis","target_id":"NFE2L2","target_type":"gene","relation":"candidate_master_transcription_factor"},{"source_id":"H7","source_type":"hypothesis","target_id":"REST","target_type":"gene","relation":"candidate_master_transcription_factor"},{"source_id":"H7","source_type":"hypothesis","target_id":"STAT3","target_type":"gene","relation":"candidate_master_transcription_factor"},{"source_id":"H4","source_type":"hypothesis","target_id":"H5","target_type":"hypothesis","relation":"shares_mechanistic_overlap_proteostasis_and_inflammation_interconnected"},{"source_id":"H1","source_type":"hypothesis","target_id":"H6","target_type":"hypothesis","relation":"both_involve_LRP1_mediated_processes"},{"source_id":"H2","source_type":"hypothesis","target_id":"H4","target_type":"hypothesis","relation":"metabolic_state_modulates_autophagic_capacity"}]}